EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects

Juan Jin, Cuiping Huang, Changhai Zhu, Wanni Feng, Ang He, Tuo Li, Lina Wang, Xiaolu Wang, Xiali Rao, Fangliang Gan

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Juan Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Office of Drug Clinical Trial Institution, Xianning Central Hospital, First Affiliated Hospital of Hubei University of Science and Technology, Xianni…. Hauptthemen laut MEDLINE: East Asian People, Esomeprazole. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Key Projects of Xianning Science and Technology Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This bioequivalence study is critically important for drug production. Recently, a local pharmaceutical company produced esomeprazole magnesium enteric‐coated capsules, a major drug to help to eradicate Helicobacter pylori , but the bioequivalence is not well known. The present study aimed to evaluate the bioequivalence of the 2 esomeprazole magnesium enteric‐coated capsules and their pharmacokinetics and safety in 3 biological equivalence trials: fasting, feeding, and mixing. The fasting and mixing trials used single‐centered randomized, open‐label, single‐dose, 2‐treatment, 2‐period, and 2‐sequence crossover design, while the fed trials used single‐centered, randomized, open‐label, single‐dose, 2‐treatment, 3‐period, 3‐sequence partial crossover design. For the fasting and mixing trials, each of the 32 subjects was fasted overnight prior to taking the test preparations or reference preparations. In the fed trial, 54 subjects were given a high‐fat meal 1 hour before the drugs were administered. Blood specimens from all subjects were collected against the light within 14 hours, with the plasma drug concentration being detected by the validated ultra‐performance liquid chromatography–tandem mass spectrometry analysis method. Geometric mean ratio of maximum concentration, the area under the concentration–time curve from time zero to the last measurable concentration, and area under the concentration–time curve from time zero to infinity with 90% confidence interval were calculated. The data from fasting, mixing, and fed trials met the bioequivalence criteria. No serious adverse reactions were found, suggesting that the test and reference preparations of esomeprazole magnesium enteric capsules have similar safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

East Asian PeopleEsomeprazoleHumansBiological AvailabilityCapsulesHealthy VolunteersHelicobacter InfectionsHelicobacter pyloriTablets, Enteric-CoatedTherapeutic EquivalencyRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

bioequivalenceesomeprazolepharmacokineticssafetyultra-performance liquid chromatography-tandem mass spectrometry

Substanzen

CapsulesEsomeprazoleTablets, Enteric-Coated

Autor:innen und Institutionen

  • Office of Drug Clinical Trial Institution, Xianning Central Hospital, First Affiliated Hospital of Hubei University of Science and Technology, Xianning, China.
  • School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
  • School of Clinical Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.

Förderung

  • Key Projects of Xianning Science and Technology Plan

Zitieren

APA

Jin, J., Huang, C., Zhu, C., Feng, W., He, A., Li, T., Wang, L., Wang, X., Rao, X., & Gan, F. (2023). Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1273

Vancouver

Jin J, Huang C, Zhu C, Feng W, He A, Li T, et al. Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1273

BibTeX
@article{Jin2023,
  author = {Jin, Juan and Huang, Cuiping and Zhu, Changhai and Feng, Wanni and He, Ang and Li, Tuo and Wang, Lina and Wang, Xiaolu and Rao, Xiali and Gan, Fangliang},
  title = {Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1273}
}
Kostenlos starten →